Table 1.
Performance evaluation of the CapitalBio™ DNA microarray for rifampin and isoniazid resistance in tuberculosis cases compared with the standard drug sensitivity testing (DST) method for the 671 samples
| CapitalBio™ DNA microarray | Conventional drug susceptibility testing | ||||||||
|---|---|---|---|---|---|---|---|---|---|
| No.susceptible (%) | No.resistant (%) | Total No. | Sensitivity (%) | Specificity (%) | AR | PPV (%) | NPV (%) | Kappa | |
| Rifampin | 83.1 | 98.7 | 93.9 | 96.6 | 92.9 | 0.85 | |||
| Susceptible | 458 (98.7) | 35 (16.9) | 493 | ||||||
| Resistant | 6(1.3) | 172 (83.1) | 178 | ||||||
| Total | 464 | 207 | 671 | ||||||
| Isoniazid | 79.9 | 99.6 | 93.1 | 98.8 | 91.1 | 0.84 | |||
| Susceptible | 450 (99.3) | 44 (20.5) | 494 | ||||||
| Resistant | 2 (0.7) | 175 (79.5) | 177 | ||||||
| Total | 452 | 219 | 671 | ||||||
Abbreviations: PPV positive predictive value, NPV negative predictive value, AR agreement rate